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1-5 Although NAC does not improve survival compared with adjuvant therapy, 6 a survival benefit has been demonstrated for the use of additional chemotherapy in patients who do not achieve a pathologic complete response (pCR) 7 with NAC. The paradigms for local therapy of the breast and axilla were developed on the basis of trials of initial surgical treatment. The increasing use of NAC has raised questions about the optimal approach to the axilla, including accuracy and timing of sentinel lymph node biopsy (SLNB) in patients who are clinically node negative (cN0) at presentation, use of NAC to avoid axillary lymph node dissection (ALND) in patients presenting with node-positive (cN+) disease, and the relative importance of pre-and post-NAC stage in predicting the risk of locoregional recurrence (LRR). Herein we review the controversies and unanswered questions regarding axillary management in patients receiving NAC.
Concerns Regarding Feasibility of SLNB After NAC
Initially, there was concern that fibrosis in lymphatic channels as tumor emboli responded to treatment would result in altered lymphatic drainage in the breast and that a nonuniform response to treatment in the axillary nodes would cause an unacceptably high falsenegative rate (FNR) for SLNB after NAC. Early studies reporting sentinel lymph node (SLN) identification rates following NAC ranging from 63% to 100%, as well as FNRs of 0% to 33%, [8] [9] [10] [11] substantiated these concerns. There was wide variation in the stage of patients included in these reports, and bulky nodal disease at presentation or persistent adenopathy following NAC significantly affects the accuracy of SLNB. Subsequent studies examining more well-defined patient subsets established the feasibility of SLNB after NAC.
Clinically Node-Negative Patients
Studies examining the accuracy of SLNB after NAC in patients presenting with cN0 disease report similar identification rates and FNRs to those seen in the upfront surgery setting. The GANEA study was a prospective multi-institutional European trial assessing the feasibility of SLNB following NAC in both cN0 and cN+ cohorts. Among 130 patients with cN0 disease, the SLN identification rate was 95% with an FNR of 9%; the 82% identification rate seen among patients with cN+ disease (P=.008) was significantly lower. 12 A singleinstitution retrospective study of patients with cN0 disease from MD Anderson Cancer Center (MDACC) included 3171 patients undergoing upfront surgery and 575 patients who underwent SLNB following NAC. Sentinel lymph node identification rates and FNRs were not significantly different, with identification rates of 99% and 97%, and FNRs of 4% and 6%, respectively. 13 Several study-level metaanalyses including more than 5000 patients treated with SLNB after NAC report SLN identification rates of 90% to 94% and FNRs of 7% to 12%. 8, 9, 14, 15 A persistent finding in studies comparing upfront SLNB to SLNB after NAC is a lower rate of nodal positivity in the post-NAC group. In the 1097 patients with cN0 disease enrolled in the National Surgical Adjuvant Breast and Bowel Project (NS-ABP) B-18 trial comparing preoperative vs postoperative doxorubicin and cyclophosphamide chemotherapy, there was a significant reduction in node-positive disease in women undergoing NAC (33% vs 48%; P<.001).
2 Subsequently, NSABP B-27 reported significantly greater reductions in nodal involvement in women receiving preoperative docetaxel in addition to doxorubicin and cyclophosphamide compared with those receiving neoadjuvant doxorubicin and cyclophosphamide alone (40% vs 49%; P < .001). 1 In the MDACC experience, a statistically significant reduction in nodal metastases was seen for T2 and T3 tumors, with a similar but nonsignificant finding observed for T1 tumors (13% vs 19%; P = .2) 13 (Table 1) . 1, 2, 13 In aggregate, these studies support the feasibility of SLNB following NAC in patients with cN0 disease and highlight the potential to downstage microscopic nodal disease and avoid ALND. While the FNRs of SLNB appear similar among patients with cN0 disease staged prior to NAC vs those undergoing SLNB following NAC, the long-term consequence of leaving lymph nodes with potentially chemoresistant disease in situ has raised concern. Information to address this question is limited because the majority of studies of SLNB after NAC required completion ALND to establish the accuracy of the procedure. In the MDACC series, 409 of 444 women with a negative SLNB following NAC were managed with an SLNB alone. With a median follow-up of 47 months, the 1.2% rate of regional recurrence did not differ significantly from the 0.9% rate observed in 3171 patients having a negative upfront SLNB. 13 In a second study including 15 women with a negative SLNB following NAC, no axillary recurrences were observed at a median follow-up of 52 months. trials demonstrate that residual disease in the breast and axilla following NAC is a more important predictor of LRR than pretreatment stage. Among patients with cN0 disease undergoing breastconserving surgery following NAC, rates of regional recurrence at 10 years were low (Յ2%), regardless of final pathologic status. Conversely, among patients with cN+ disease, those achieving a nodal pCR had low rates of regional recurrence (Յ2%), while those who remained pathologically node positive had the highest rates of regional recurrence (8%-9%). For patients undergoing mastectomy after NAC, lack of a nodal pCR was the strongest predictor of 10-year LRR (HR, 4.5; 95% CI, 1.6-12.2; P<.001). These results suggest that the posttreatment pathological response to NAC may allow a more personalized radiotherapy treatment plan than that derived from a pretreatment SLNB, and eliminate much of the rationale for pre-NAC axillary staging, whether by ultrasound and fine-needle aspiration or SLNB in patients with cN0 disease. In our opinion, axillary staging prior to NAC should be reserved for the unusual circumstance in which the identification of nodal metastases would provide the indication for NAC.
Clinically Node-Positive Disease
The decrease in nodal metastases in patients with cN0 disease undergoing post-NAC axillary staging and the increasing rates of pCR in the breast in patients treated with current chemotherapy regimens led to the study of SLNB among patients presenting with cN+ disease. Table 3 summarizes data from 3 prospective, multiinstitutional trials assessing the accuracy of SLNB after NAC among patients with cN+ disease. As mentioned, the SENTINA study was a 4-arm study undertaken at 103 centers across Germany and Austria between 2009 and 2012. Patients were stratified based on both pre-and postchemotherapy clinical nodal status, which was assigned by physical examination and axillary ultrasound. Histologic confirmation of metastases in clinically suspicious nodes was not mandatory. Patients converting from cN+ to cN0 following NAC (n =592) had an SLN detection rate of only 80%, with improved detection with the use of dual radiocolloid and blue dye compared with radiocolloid alone (88% vs 77%). The overall FNR was 14%; dual-tracer mapping vs radiocolloid alone resulted in FNRs of 9% vs 16%, respectively, although mapping technique was not significantly associated with the FNR on multivariate analysis (P=.15). The FNR with removal of 3 or more SLNs was 7% or less, compared with 19% with 2 nodes removed and 24% with only 1 SLN removed (P=.008).
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The American College of Surgeons Oncology Group (ACOSOG) Z1071 trial also assessed the feasibility of SLNB following NAC in patients presenting with cN+ disease confirmed by biopsy. 32 The primary study end point was an FNR of 10% or less. Unlike the SENTINA study, conversion from cN+ to cN0 was not mandated, but patients were required to have at least 2 SLNs identified to be included in the calculation of the FNR. Surgery was completed by 649 patients with cN1 disease at presentation. Following NAC, 83% were cN0 by physical examination, 13% had residual palpable adenopathy, and clinical axillary status was unknown in 4%. At least 1 SLN was identified in 639 (93%) patients. The FNR among women who had at least 2 SLNs excised was 13% and failed to meet the predefined 10% rate to consider the procedure successful. In unplanned, exploratory analyses, a significant reduction in the FNR was seen with the use of dual-tracer mapping (dual-tracer FNR, 11% vs 20% with single agent; P = .05) and with the removal of at least 3 SLNs (FNR, 9% with Ն3 SLNs, 21% with 2 SLNs; P=.007). On multivariable modeling, only number of SLNs excised (2 vs Ն3) remained significantly associated with the FNR. Similar in design, the Sentinel Node Biopsy Following Neoadjuvant Chemotherapy (SN FNAC) study enrolled biopsy-proven patients with cN+ disease to examine the technical success of SLNB following NAC with a predefined optimal identification rate of 90% and an FNR of 10% or less. Pathologic evaluation of the SLNs was performed with immunohistochemical analysis, as well as routine staining. The trial closed early following accrual of 51% of the target population (n = 153) given the findings of the SENTINA and AGOCOSG Z1071 trials. Results included an overall identification rate of 88% and an FNR of 8% when isolated tumor cells were considered node positive. The FNR was 13% when isolated tumor cells were not considered metastases as is standard in the upfront surgical setting.
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The overall FNRs greater than 10% in the SENTINA and ACOSOG Z1071 trials were believed to be unacceptably high, and the trials were considered to have negative results. However, technical modifications, including use of dual tracer and retrieval of at least 3 SLNs, resulted in clinically acceptable FNRs of less than 10% (Table 4) . 20, 26, 32 The need to identify 3 or more SLNs for accurate post-NAC staging potentially limits the use of SLNB given that the median number of SLNs retrieved in trials in the primary surgical setting was 2. [33] [34] [35] In ACOSOG Z1071 and SENTINA, only 56% and 34% of patients had 3 or more SLNs removed. 20, 32 Mamtani et al 28 examined the likelihood of identifying more than 2 SLNs after NAC in a prospective, consecutive cohort of 155 patients with biopsy-proven cN1 disease. Following NAC, 132 converted to cN0 and underwent SLNB with dualagent mapping. Axillary lymph node dissection was performed for any residual nodal tumor. Routine immunohistochemical analysis was not used. An SLN was identified in 98% of cases, and at least 3 SLNs were retrieved in 110 cases (86%). Axillary lymph node dissection was performed for positive SLNs (n = 54), failed mapping (n = 3), fewer than 3 SLNs identified (n =9), or on the basis of intraoperative findings (n =4). Based on this algorithm, 47% of patients with cN1 disease who converted to cN0 following NAC were spared ALND.
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Additional Techniques to Optimize SLNB Following NAC Marking abnormal axillary lymph nodes at the time of needle biopsy with either a clip or by tattooing to allow for localization and excision of the known metastatic node following NAC has been suggested as a strategy to reduce the FNR. 29, [36] [37] [38] [39] Studies examining the combination of SLNB and excision of the clipped node report that the clipped lymph node is not an SLN in 9% to 24% of cases and that the combination of SLNB with targeted excision of the clipped node reduces the FNR. 29, 36, 40 One caveat in evaluating the benefit of clipping nodes is variability in the SLNB techniques used and failure to control for the number of SLNs removed, making it difficult to determine the benefit of nodal clipping when SLNB technique and pathologic evaluation are optimized. Clear evidence of benefit of nodal clipping is important, because clipped nodes require localization with either a wire or a radioactive seed. Wires in the axilla may be difficult to place and are uncomfortable, while clips not centrally placed in nodes may fall out when the node responds to chemotherapy, leading to placement of a radioactive seed in the axillary fat, which may be difficult to retrieve. Although retained seeds are not harmful, they are reportable radiation safety events in some states. Another approach to documenting removal of nodes that were positive prior to NAC is the identification of posttreatment changes in the node on pathologic examination. Barrio et al 41 identified treatment effect in 94% (192 of 204) of nodal specimens in patients with documented metastases before NAC who had a nodal pCR. Factors significantly associated with the likelihood of identifying treatment effect include tumor subtype (83% hormone receptor positive/ human epidermal growth factor receptor 2 [HER2] negative, 96% triple negative, 96% of HER2-positive tumors; P=.05) and the pathologic response in the breast (treatment effect present in 97% compared with 89% of those with and without a breast pCR, respectively; P=.05). Among SLNB patients, SLNs with treatment effect were retrieved in 88% of women with at least 3 SLNs removed without marking the biopsied node. 41 However, even among patients undergoing ALND, treatment effect was not seen in 3%. A major unanswered question regarding the use of SLNB alone in patients who convert from cN+ to cN0 is the rate of nodal recurrence. Although FNRs of 5% to 10% in the primary surgical setting are associated with axillary failure in less than 1% of patients, [42] [43] [44] residual disease after NAC is by definition drug resistant and may result in higher rates of regional recurrence. Information on nodal recurrence is not available from the prospective studies discussed because all required ALND to determine the FNR. 20, 26, 32 In spite of this, growing numbers of surgeons are comfortable omitting ALND among women after a nodal pCR. 45 Available data suggest that some combination of techniques (dual mapping, retrieval of >2 SLNs, nodal marking) should be considered when SLNB is used in patients with cN+ disease who convert to cN0 following NAC to minimize the FNR. Current National Comprehensive Cancer Network guidelines endorse the use of post-NAC SLNB for axillary staging in patients with cN+ disease who convert to clinically node negative following systemic therapy. 18 In our practice, SLNB following NAC with dualtracer mapping and retrieval of 3 or more negative SLNs are required to eliminate ALND in patients presenting with nodal metastases who become cN0.
Role of Regional Radiation Therapy
While nodal irradiation after SLNB has been proven as a safe alternative to ALND among patients with 1 or 2 positive nodes undergoing primary surgery, 46 the optimal combination of surgery and radiation therapy after NAC remains unknown. Traditionally, the pre-NAC stage has been the determinant of the need for nodal irradiation. A National Cancer Database retrospective review of 1560 patients with cN+ disease with nodal pCR following NAC evaluated the role of postmastectomy radiation therapy (PMRT) among this cohort. Postmastectomy radiation therapy was administered to 58% of patients, with PMRT significantly more common among patients with higher T or N stage and hormone receptor negativity. At a median follow-up of 56 months, no statistical difference in overall survival was observed between groups. On subgroup analyses, PMRT was associated with a significant improvement in overall survival for patients with clinical stage IIIB/IIIC disease, or residual invasive disease in the breast following NAC (P < .05). 47 As previously discussed, in a retrospective analysis of data from the NSABP trials of NAC in which PMRT was prohibited and node field irradiation was not used after BCT, Mamounas et al 31 noted that residual disease in the axillary nodes after NAC was the strongest predictor of LRR, and that risk was low in patients with negative nodes and residual disease in the breast. Prospective data addressing the need for radiotherapy after nodal pCR will come from the NSABP B-51 trial, a randomized trial enrolling patients with stage II to III breast cancer with biopsyconfirmed nodal metastases who convert to ypN0 (staged by SLNB or ALND) following NAC. 48 Mastectomy patients are randomized to chest wall and regional nodal irradiation vs no radiation, while lumpectomy patients are randomized to whole-breast irradiation with or without nodal treatment. The need for ALND in women with residual nodal disease after NAC is addressed in the ALLIANCE A011202 trial (NCT01901094) comparing overall survival, LRR, and lymphedema outcomes after ALND vs axillary nodal irradiation among women who undergo SLNB and have residual nodal disease. It is possible that the effectiveness of radiotherapy without ALND will vary based on the hormone receptor and HER2 status of the tumor, given that failure to achieve pCR in patients with triple-negative breast cancer is strongly associated with a poor outcome, 49 while the same relationship is not seen in patients with estrogen receptor-positive cancers who have the benefit of 5 to 10 additional years of endocrine therapy.
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Together, these 2 studies address the ability to individualize a patient's axillary management based on response to NAC to both maximize regional control and minimize therapeutic morbidity. While awaiting the results, ALND remains standard for patients with tumor in the axillary nodes after NAC, including those with micrometastases. In determining the need for nodal and chest wall irradiation in patients who have a nodal pCR, we consider the presenting stage, presence of pCR in the breast, and other factors known to influence local control such as age, lymphovascular invasion, hormone receptor status, and HER2 status to identify lowrisk women unlikely to benefit from radiotherapy. In a prospective, consecutive series of 287 patients with positive SLNs who met ACOSOG Z0011 eligibility, only 16% had indications for ALND for either at least 3 positive SLNs or gross extracapsular extension.
51 Subsequently, the same group reported a cohort of 701 consecutive cT1-2N0 patients with a positive SLN and found no difference in the likelihood of ALND among high-risk patients, defined as women 50 years or younger, or with triple-negative or HER2-amplified tumors compared with postmenopausal women with estrogen receptor-positive cancers, with 13% and 12% of each group having at least 3 positive SLNs (P=.82). 52 While these results indicate that a minority of women with cN0 disease undergoing breastconserving therapy require ALND, it may be possible to reduce this rate among selected patients, and, importantly, these results do not apply to women undergoing mastectomy. Rates of nodal pCR with NAC differ based on tumor subtype, 18 ranging from 40% to 60% overall, and approaching 70% to 80% among patients with triplenegative and HER2-amplified tumors (Table 5) . 25, [27] [28] [29] 48, 53 Patients with cN0 disease with these subtypes, even when undergoing breast-conserving surgery, may have a higher likelihood of avoiding ALND with definitive axillary staging following NAC, a concept that warrants further study. In patients with cN+ disease, it is clear that NAC offers the only possibility of avoiding ALND.
Conclusions
The demonstration that SLNB accurately stages the axilla after NAC regardless of the presenting nodal stage (cN0, cN1) provides an important rationale for the use of NAC for axillary downstaging in patients who are candidates for breast-conserving surgery at presentation or who desire mastectomy. Sentinel lymph node identification rates and FNRs in those who have cN0 disease are similar to those seen with initial SLN surgery, and nodal recurrence after a negative SLNB result is uncommon. In patients with cN1 disease, modification of the SLNB technique is needed to minimize the FNR, and the optimal method remains under study but should include dual-tracer mapping and removal of more than 2 sentinel nodes. The rate of regional recurrence in patients with proven nodal metastases who have a pCR and undergo SLNB alone is uncertain. A major unresolved question is the relative importance of the pre-NAC nodal stage vs the post-NAC nodal stage in determining the risk of LRR and the need for radiotherapy. Ongoing clinical trials will address this issue. For cN0 patients with estrogen receptor-positive, HER2-negative cancers undergoing breast-conserving therapy, initial surgery is the path most likely to avoid ALND. The optimal approach to cN0 patients with triplenegative or HER2-overexpressing cancers is uncertain, but for patients undergoing mastectomy, and those with biopsy-proven nodal metastases, NAC reduces the likelihood of ALND. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
